Skip to main content

Fatty liver Nano-/Antibody Therapy - (FAITH)

Project description

A novel antibody therapy against non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease is strongly associated with poor nutrition and obesity, often leading to non-alcoholic steatohepatitis (NASH), fibrosis and liver cancer. Anti-platelet therapy has emerged as a potential strategy against NASH but exhibits adverse health effects. Researchers of the EU-funded FAITH project have previously shown that blocking the platelet-derived surface molecule GPIba prevents NASH and liver cancer in experimental models without any side effects. With this project, they plan to generate antibodies to block the binding of thrombin to GPIba without interfering with its role in platelet-derived aggregation and haemostasis.

Host institution

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Net EU contribution
€ 150 000,00
Address
Im Neuenheimer Feld 280
69120 Heidelberg
Germany

See on map

Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Other funding
No data

Beneficiaries (1)

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Germany
Net EU contribution
€ 150 000,00
Address
Im Neuenheimer Feld 280
69120 Heidelberg

See on map

Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Other funding
No data